financetom
Business
financetom
/
Business
/
Nasdaq Benefiting From Capital Markets Recovery, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nasdaq Benefiting From Capital Markets Recovery, Morgan Stanley Says
Nov 20, 2025 11:53 AM

11:30 AM EST, 11/20/2025 (MT Newswires) -- Nasdaq (NDAQ) is seen as an "attractive play" on capital markets recovery and a business transformation story as the company shifts to higher quality recurring revenue streams, Morgan Stanley said in a note Thursday.

Revenue growth will likely accelerate across its solutions business into 2026 to 2027 as capital markets recovery ramps, while a supportive macro backdrop for risk assets into 2026 is expected to boost index revenue and support Nasdaq's workflow and insights businesses, according to the note.

The investment firm said the cyclical and secular tailwinds driving Nasdaq's execution momentum will likely catalyze a re-rating toward info services comps.

As Nasdaq's shares are up 13% year to date, lagging the valuation of peers' shares that increased 18%, Morgan Stanley said it sees an attractive entry point into the stock.

The firm raised its 2026 and 2027 earnings per share estimates for Nasdaq by 6.9% and 9.4%, respectively, to $3.85 and $4.42.

Morgan Stanley upgraded Nasdaq to overweight from equal-weight, and lifted the price target to $110 from $97.

Price: 87.37, Change: +1.35, Percent Change: +1.57

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million
Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million
May 30, 2024
09:33 AM EDT, 05/30/2024 (MT Newswires) -- Day One Biopharmaceuticals ( DAWN ) said Thursday it sold its priority review voucher for $108 million to an undisclosed buyer. The company said it was awarded the voucher after the US Food and Drug Administration's accelerated approval of Ojemda, or tovorafenib. As part of the deal, $8.1 million of the amount received...
Salesforce Stock Is Tumbling Thursday: What's Going On?
Salesforce Stock Is Tumbling Thursday: What's Going On?
May 30, 2024
Salesforce Inc ( CRM ) shares are trading lower Thursday after the company reported first-quarter financial results and issued weak guidance for the second quarter. Multiple analysts also lowered price targets following the print. Q1 Revenue: $9.13 billion, versus estimates of $9.147 billion Q1 EPS: $2.44, versus estimates of $2.38 Salesforce ( CRM ) reported its first top-line miss in more than...
Foot Locker's Slight Q1 Beat, Guidance Reiteration Seem to Have Satisfied Investors, Wedbush Says; Shares Rise Pre-Bell
Foot Locker's Slight Q1 Beat, Guidance Reiteration Seem to Have Satisfied Investors, Wedbush Says; Shares Rise Pre-Bell
May 30, 2024
09:22 AM EDT, 05/30/2024 (MT Newswires) -- Foot Locker ( FL ) appears to have satisfied investors after reporting fiscal Q1 results that slightly beat analyst estimates and reiterating its fiscal 2024 guidance, Wedbush Securities said Thursday. On Thursday, the company reported fiscal Q1 adjusted EPS of $0.22, down from $0.70 a year earlier. Analysts polled by Capital IQ expected...
Correction: Foot Locker Fiscal Q1 Adjusted Earnings, Revenue Decline; Shares Advance Pre-Bell
Correction: Foot Locker Fiscal Q1 Adjusted Earnings, Revenue Decline; Shares Advance Pre-Bell
May 30, 2024
09:20 AM EDT, 05/30/2024 (MT Newswires) -- (Corrects Capital IQ analysts' revenue estimate in the fourth paragraph.) Foot Locker ( FL ) reported fiscal Q1 adjusted earnings Thursday of $0.22 per diluted share, down from $0.70 a year earlier. Analysts polled by Capital IQ expected $0.12. Revenue for the fiscal quarter ended May 4 was $1.88 billion, down from $1.93...
Copyright 2023-2025 - www.financetom.com All Rights Reserved